Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Gene Ther. 2008 Mar 20;15(14):1024–1034. doi: 10.1038/gt.2008.30

Figure 5.

Figure 5

(a) Fluorescence-activated cell sorting (FACS) analysis for CD46 expression, demonstrated no difference in measles virus receptor CD46 expression prior to and following geldanamycin (GA) treatment. (b) Assessment of viral replication in MV-CEA/GA combination-treated cells. One-step viral growth curves demonstrated that GA treatment did not increase the proliferation of MV-CEA in either MDA-MB-231 or SKOV3.IP cells. Both western immunoblotting (c), and QRT-PCR for measles virus N mRNA (d) showed no significant difference in N-protein expression in MV-CEA or viral genome copy number/GA combination-treated cells, as compared to MV-CEA treatment alone. (e) Similarly, there was no difference in CEA transgene expression between single-agent GA and combination-treated cells. (f) Total and cell surface hemaglutinin (H) protein expression levels were estimated by immunoblotting of cell lysates or of surface-biotinylated proteins immunoprecipitated with anti-FLAG antibody. There was no increase in H protein expression in combination-treated cells.